Thursday, May 13, 2021 4:18:34 PM
CW brought in Novatech and ran the AUS/NZ IPF/CC failures and then the SK mess. Our current Science Team ran the COVID Trial (mostly) which is NOW showing results that the Past Science officer barely called 'Trends' at the Interim data release. P=<.04/.03/.01. WTF?
It was His * time to provide positive encouragement of the Ifenprodil Trial Results for AGN and Shareholders, but apparently his mind was busy elsewhere.
*CW=Flakley Foont, IMO.
AGN is now picking up the pieces of these presentations regarding the COVID Trial results and is finally giving the CEO some better cards. I am again willing to see what plays out. (ie at a 25%+ discount)
The association of IPF/CC with the COVID Ifenprodil results is pretty important, IMO.
Maybe some folks tolerance of AGN has waned. Maybe take a break or move on to reduce stress. Get laid. Get tiny. It's a "Speculative OTC" investment. I wouldn't sell now, it's time to BUY, IMHFO! ...GLTA...
FEATURED Cannabix Technologies and Omega Laboratories Inc. enter Strategic Partnership to Commercialize Marijuana Breathalyzer Technology • May 16, 2024 8:13 AM
ILUS Provides a First Quarter Filing Update • ILUS • May 16, 2024 11:26 AM
Avant Technologies to Revolutionize Data Center Management with Proprietary AI Software Platform • AVAI • May 16, 2024 8:00 AM
HealthLynked Corp Announces First Quarter 2024 Results: Achieves 8% Revenue Growth Over Last Quarter • HLYK • May 16, 2024 8:00 AM
Integrated Ventures Files Q3/2024 With Mining Revenues Of $1,983,250 And Positive Earnings Of $0.05 Cents Per Share • INTV • May 15, 2024 10:30 AM
Swifty Global Announces Impressive Financial Results for Q1 2024 • DRCR • May 15, 2024 10:25 AM